| 2.02 -0.06 (-2.88%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.7 | 1-year : | 2.95 |
| Resists | First : | 2.31 | Second : | 2.52 |
| Pivot price | 2.07 |
|||
| Supports | First : | 1.96 | Second : | 1.63 |
| MAs | MA(5) : | 2.05 |
MA(20) : | 2.12 |
| MA(100) : | 2.6 |
MA(250) : | 2.08  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 22.8 |
D(3) : | 22.9 |
| RSI | RSI(14): 41.2 |
|||
| 52-week | High : | 5.48 | Low : | 0.4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ABVC ] has closed above bottom band by 18.3%. Bollinger Bands are 65.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.1 - 2.11 | 2.11 - 2.12 |
| Low: | 1.99 - 2 | 2 - 2.02 |
| Close: | 2 - 2.02 | 2.02 - 2.04 |
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Wed, 28 Jan 2026
Is ABVC BioPharma Inc. forming a breakout pattern - July 2025 Selloffs & Safe Entry Point Alerts - mfd.ru
Mon, 03 Nov 2025
ABVC: Q3 2025 revenue surged on licensing deals, but losses and liquidity risks persist - TradingView
Mon, 03 Nov 2025
ABVC BIOPHARMA, INC. SEC 10-Q Report - TradingView
Mon, 03 Nov 2025
ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025 - Yahoo Finance
Fri, 31 Oct 2025
ABVC BioPharma Receives Additional US$100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US$695,950 - NewMediaWire
Tue, 23 Sep 2025
ABVC BioPharma, Inc. (ABVC) Reports 103% Asset Surge, Eyeing Phase III Trials for Depression Therapies - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 24 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 11.3 (%) |
| Held by Institutions | 3.2 (%) |
| Shares Short | 347 (K) |
| Shares Short P.Month | 377 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.5 |
| Profit Margin | 0 % |
| Operating Margin | -146.6 % |
| Return on Assets (ttm) | -17.3 % |
| Return on Equity (ttm) | -47.8 % |
| Qtrly Rev. Growth | 104.5 % |
| Gross Profit (p.s.) | 0.03 |
| Sales Per Share | 0.03 |
| EBITDA (p.s.) | -0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -7.22 |
| PEG Ratio | 0 |
| Price to Book value | 3.96 |
| Price to Sales | 61.51 |
| Price to Cash Flow | -21.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|